FDA Hold on Vanda’s Long-Term Human Digestive Drug Testing OK’d

February 4, 2020

Vanda Pharmaceuticals Inc. may not begin long-term human testing for tradipitant, a drug designed to treat a chronic digestive disorder, until it completes a long-term toxicity study on animals other than rodents, a federal court in the District of Columbia said.

Related Stories